Details of the Drug Combinations

General Information of This Drug (ID: DMAT8CG)

• Drug Name: Goserelin (DMAT8CG)
• Synonyms: AstraZeneca (TN); HS-2015; ZD-9393; Zoladex (TN)

Indication

Breast cancer; ICD 11: 2C60-2C65; Status: Approved [1]; Estrogen-receptor positive breast cancer; ICD 11: N.A.; Status: Approved [2]; Endometriosis; ICD 11: GA10; Status: Investigative [2]; Male breast carcinoma; ICD 11: N.A.; Status: Investigative [2]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

32 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Exemestane + Goserelin	DCWJATP	Exemestane	Breast Cancer	[3]
Goserelin + Flutamide	DC0VXSY	Flutamide	Prostate Cancer	[4]
Goserelin + Bicalutamide	DC1URFF	Bicalutamide	Prostate Cancer	[5]
Goserelin + Tamoxifen	DCGEM4X	Tamoxifen	Breast Cancer	[6]
Goserelin + Anastrozole	DCLJVYT	Anastrozole	Breast Cancer	[7]
Goserelin + Tamoxifen	DCWUJU0	Tamoxifen	Early-stage Breast Cancer	[8]
Goserelin + Docetaxel	DC520FJ	Docetaxel	Prostate Cancer	[9]
Leuprolide + Goserelin	DCHVXZQ	Leuprolide	Prostate Cancer	[10]
Leuprolide + Goserelin	DC6Z3D7	Leuprolide	Recurrent Prostate Cancer	[11]
Leuprolide + Goserelin	DCTGJYL	Leuprolide	Prostate Cancer	[12]
Leuprolide + Goserelin	DCD7XMI	Leuprolide	Adenocarcinoma of the Prostate	[13]
ABIRATERONE + Goserelin	DC6G14H	ABIRATERONE	Prostate Cancer	[14]
ABIRATERONE + Goserelin	DCQE28F	ABIRATERONE	Prostate Cancer	[15]
Everolimus + Goserelin	DC1L2BB	Everolimus	Metastatic Breast Cancer	[16]
Fulvestrant + Goserelin	DCV8UQ1	Fulvestrant	Advanced Breast Cancer	[17]
Fulvestrant + Goserelin	DCN2LA7	Fulvestrant	Metastatic Breast Cancer	[18]
Goserelin + Dutasteride	DC2MNA6	Dutasteride	Salivary Duct Carcinoma	[19]
Goserelin + Letrozole	DCCJUSF	Letrozole	Estrogen Receptor-positive Breast Cancer	[20]
Goserelin + Palbociclib	DCHIMNL	Palbociclib	Breast Neoplasms	[21]
Goserelin + Letrozole	DCLZPT8	Letrozole	Invasive Lobular Breast Carcinoma	[22]
Goserelin + Letrozole	DCN5B53	Letrozole	Metastatic Breast Cancer	[16]
Goserelin + Darolutamide	DCVGCYP	Darolutamide	Salivary Gland Cancer	[23]
Goserelin + Enzalutamide	DCXP3ZY	Enzalutamide	Prostate Cancer	[24]
Leuprolide + Goserelin	DCY45M7	Leuprolide	Breast Cancer	[25]
Leuprolide + Goserelin	DC43XRL	Leuprolide	Adenocarcinoma of the Prostate	[26]
Leuprolide + Goserelin	DCLI0V7	Leuprolide	Recurrent Prostate Cancer	[27]
Leuprolide + Goserelin	DCVMLM2	Leuprolide	Prostate Cancer	[28]
Goserelin + Letrozole	DC0IC7N	Letrozole	Advanced Metastatic Breast Cancer	[29]
Leuprolide + Goserelin	DC763GJ	Leuprolide	Prostate Cancer	[30]
Leuprolide + Goserelin	DCZXJZA	Leuprolide	Breast Cancer	[31]
Leuprolide + Goserelin	DC9C9SC	Leuprolide	Prostate Cancer	[32]
Leuprolide + Goserelin	DCW1ETX	Leuprolide	Gastrointestinal Complications	[33]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3879).
• [2] Goserelin FDA Label
• [3] ClinicalTrials.gov (NCT00432172) Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
• [4] ClinicalTrials.gov (NCT00769548) Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer
• [5] ClinicalTrials.gov (NCT00002651) SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
• [6] ClinicalTrials.gov (NCT00605267) Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
• [7] ClinicalTrials.gov (NCT00186121) Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
• [8] ClinicalTrials.gov (NCT00309478) Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
• [9] ClinicalTrials.gov (NCT00482807) Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer
• [10] ClinicalTrials.gov (NCT02366494) Micro RNAs to Predict Response to Androgen Deprivation Therapy
• [11] ClinicalTrials.gov (NCT00454571) Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
• [12] ClinicalTrials.gov (NCT00004635) Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
• [13] ClinicalTrials.gov (NCT02023463) Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
• [14] ClinicalTrials.gov (NCT02867020) Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels
• [15] ClinicalTrials.gov (NCT04736108) Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate
• [16] ClinicalTrials.gov (NCT02313051) Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
• [17] ClinicalTrials.gov (NCT04862143) Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant
• [18] ClinicalTrials.gov (NCT02072512) The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer
• [19] ClinicalTrials.gov (NCT05513365) Phase II Dutasteride in Combination With CAB vs CAB in SDC
• [20] ClinicalTrials.gov (NCT01368263) Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
• [21] ClinicalTrials.gov (NCT01723774) PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer. U.S. National Institutes of Health.
• [22] ClinicalTrials.gov (NCT04551495) Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)
• [23] ClinicalTrials.gov (NCT05694819) Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
• [24] ClinicalTrials.gov (NCT02430480) Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
• [25] ClinicalTrials.gov (NCT03056755) Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
• [26] ClinicalTrials.gov (NCT02058706) LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
• [27] ClinicalTrials.gov (NCT01750398) Bipolar Androgen-based Therapy for Prostate Cancer (BAT)
• [28] ClinicalTrials.gov (NCT02059213) A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
• [29] ClinicalTrials.gov (NCT03096847) Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
• [30] ClinicalTrials.gov (NCT00388804) External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
• [31] ClinicalTrials.gov (NCT02941926) Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
• [32] ClinicalTrials.gov (NCT00002597) Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
• [33] ClinicalTrials.gov (NCT00541047) RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery